HYPE news live: price surges after merger nod — faces resistance at $36.22, range-bound outlook

Traders Union
All News
Crypto News
HYPE surges 12.61% as price climbs

Highlights

Sonnet BioTherapeutics shareholders approved a merger with Hyperliquid Strategies Inc and Rorschach I LLC to form a Nasdaq-listed entity managing a digital asset treasury focused on the HYPE token.
The new Hyperliquid Strategies Inc will control about $888 million in assets, including $583 million in HYPE, and trade under the ticker HSI.
Hyperliquid Strategies filed with the SEC to raise up to $1 billion for further HYPE accumulation, while on-chain data shows significant internal transfers and ongoing wallet inflows.

Asset inflows and Nasdaq listing plan drive shareholder optimism

Shareholders of Sonnet BioTherapeutics Holdings have approved a merger with Hyperliquid Strategies Inc and Rorschach I LLC, creating a publicly traded entity that will manage a digital asset treasury centered on the HYPE token. The combined Hyperliquid Strategies Inc will hold around $888 million in assets, including $583 million in HYPE, and plans to list on Nasdaq under the ticker HSI. Following this, Hyperliquid Strategies has filed with the SEC to raise up to $1 billion for further HYPE accumulation, while on-chain data show significant internal transfers and ongoing wallet inflows.

Bearish technical setup persists amid oversold oscillators and weak trend

Technically, HYPE sits well below all major moving averages (MA-20, MA-50, MA-200), underscoring prevailing bearish conditions across short to long timeframes. Resistance is indicated at the Ichimoku Kijun level of $36.22, with no clear support from primary indicators. The MACD D1 is negative and signals selling momentum, and the weak ADX D1 (21.89) reflects a non-trending environment. CCI (–139.58) and BBP (–2.07) highlight oversold conditions and dominant sellers, RSI (33.88) remains weak with slight oversold signals, and Stoch RSI is neutral, creating a backdrop of oscillators and momentum indicators that are bearish despite today's intraday price strength.

Range-bound trading likely as volatility and downside risks dominate

Over the next five days, a typical volatility band relative to current levels is expected between $30.00 and $36.00, given continued high annualized volatility. The probability of a sustained move above this band remains low (less than 20%), as higher timeframe momentum and trend indicators largely favor deeper declines. Price action is likely to be range-bound between dynamic resistance at $36.22 and support around $30.00. If bulls regain control and breach $36.22, HYPE could test the $36.50–$37.00 area, while a break below $30.00 would expose $28.00 as the next notable downside target.

Viktoras Karapetjanc, senior analyst at Traders Union, sees long-term promise in HYPE despite persistent bearish technicals. He notes that the merger approval and Nasdaq listing plans strongly improve sentiment and institutional appeal. Accumulation moves and fresh capital raising speak to rising confidence in fundamentals. While short-term momentum remains weak, Karapetjanc believes constructive developments may offer a launchpad for recovery on any positive shift in flows. "With robust macro and sentiment factors aligning, I see upside potential if HYPE reclaims $36.22 and stabilizes above key resistance levels."

Previously it was reported that Hyperliquid (HYPE) is trading well below short- to long-term moving averages and momentum indicators such as MACD, RSI, and ADX confirm strong bearish pressure with oversold signals dominating across oscillators. Resistance remains at the Ichimoku Kijun level, while volatility persists and the probability of a further breakdown is high amid seller control, as analysts noted continued downside momentum across all timeframes.

Source of Data: HYPE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.